For decades, psychedelic drugs like LSD, psilocybin (magic mushrooms), and cannabis have been associated with societal outliers, hedonism, and general recklessness. But research into psychedelics has come a long way, and biotech companies aiming to harness the therapeutic potential of psychedelics are proliferating.

Disruptive biotech companies developing cell and gene therapies (CGT) and other precision medicines remain imperative for industry evolution, and specifically, Contract Development Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) will play a critical role in the coming years.

To date the platform model has wildly garnered private investment and IPO launches, as well as enticed talent.

While most of the funding for biotech startups developing novel therapeutics has stalled in the past year as VCs take a more conservative approach and focus on companies already generating revenue through multiple streams, demand for therapies has not decreased.

Over the last decade, professionals working in the Life Sciences understand that change has been the only constant.

It wasn’t long ago when the term “artificial intelligence” (AI) conjured up images of hyper realistic human robots or flying cars.

It is a guarantee as a life sciences executive search consultant that an initial prescreen with a talented candidate will inevitably include a conversation around “a great company culture.”